Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
<p>Tocilizumab (TCZ) and Dexamethasone are used for the treatment of critically ill COVID-19 patients. We compared the short-term survival of critically ill COVID-19 patients treated with either TCZ or Dexamethasone. 109 critically ill COVID-19 patients randomly assigned to either TCZ therapy...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513566704402432 |
|---|---|
| author | Alaa Rashad (14152917) |
| author2 | Sherif Mousa (14152920) Hanaa Nafady-Hego (11506571) Asmaa Nafady (14152923) Hamed Elgendy (11570543) |
| author2_role | author author author author |
| author_facet | Alaa Rashad (14152917) Sherif Mousa (14152920) Hanaa Nafady-Hego (11506571) Asmaa Nafady (14152923) Hamed Elgendy (11570543) |
| author_role | author |
| dc.creator.none.fl_str_mv | Alaa Rashad (14152917) Sherif Mousa (14152920) Hanaa Nafady-Hego (11506571) Asmaa Nafady (14152923) Hamed Elgendy (11570543) |
| dc.date.none.fl_str_mv | 2022-11-22T21:17:17Z |
| dc.identifier.none.fl_str_mv | 10.1038/s41598-021-88086-x |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Short_term_survival_of_critically_ill_COVID-19_Egyptian_patients_on_assisted_ventilation_treated_by_either_Dexamethasone_or_Tocilizumab/21598230 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medical microbiology Multidisciplinary |
| dc.title.none.fl_str_mv | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Tocilizumab (TCZ) and Dexamethasone are used for the treatment of critically ill COVID-19 patients. We compared the short-term survival of critically ill COVID-19 patients treated with either TCZ or Dexamethasone. 109 critically ill COVID-19 patients randomly assigned to either TCZ therapy (46 patients) or pulse Dexamethasone therapy (63 patients). Age, sex, neutrophil/ lymphocyte ratio, D-dimer, ferritin level, and CT chest pattern were comparable between groups. Kaplan–Meier survival analysis showed better survival in Dexamethasone group compared with TCZ (P = 0.002), patients didn’t need vasopressor at admission (P < 0.0001), patients on non-invasive ventilation compared to patients on mechanical ventilation (P<0.0001 ), and in patients with ground glass pattern in CT chest (P<0.0001 ) compared with those who have consolidation. Cox regression analysis showed that, TCZ therapy (HR = 2.162, 95% CI, 1.144–4.087, P <0.0001) compared with Dexamethasone group, higher neutrophil/Lymphocyte ratio (HR = 2.40, CI, 1.351–4.185, P = 0.003), lower PaO2/FiO2, 2 days after treatment, (HR = 1.147, 95% CI, 1.002–1.624, P < 0.0001) independently predicted higher probability of mortality. Dexamethasone showed better survival in severe COVID-19 compared to TCZ. Considering the risk factors mentioned here is crucial when dealing with severe COVID-19 cases.</p> <p>Clinical trial registration No clinicalTrials.gov: Nal protocol approved by Hospital Authorities, for data collection and for participation in CT04519385 (19/08/2020).</p><h2>Other Information</h2> <p> Published in: Scientific Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1038/s41598-021-88086-x" target="_blank">http://dx.doi.org/10.1038/s41598-021-88086-x</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_cf25fada46e00eae0c7fe550b4bd7418 |
| identifier_str_mv | 10.1038/s41598-021-88086-x |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21598230 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or TocilizumabAlaa Rashad (14152917)Sherif Mousa (14152920)Hanaa Nafady-Hego (11506571)Asmaa Nafady (14152923)Hamed Elgendy (11570543)Medical microbiologyMultidisciplinary<p>Tocilizumab (TCZ) and Dexamethasone are used for the treatment of critically ill COVID-19 patients. We compared the short-term survival of critically ill COVID-19 patients treated with either TCZ or Dexamethasone. 109 critically ill COVID-19 patients randomly assigned to either TCZ therapy (46 patients) or pulse Dexamethasone therapy (63 patients). Age, sex, neutrophil/ lymphocyte ratio, D-dimer, ferritin level, and CT chest pattern were comparable between groups. Kaplan–Meier survival analysis showed better survival in Dexamethasone group compared with TCZ (P = 0.002), patients didn’t need vasopressor at admission (P < 0.0001), patients on non-invasive ventilation compared to patients on mechanical ventilation (P<0.0001 ), and in patients with ground glass pattern in CT chest (P<0.0001 ) compared with those who have consolidation. Cox regression analysis showed that, TCZ therapy (HR = 2.162, 95% CI, 1.144–4.087, P <0.0001) compared with Dexamethasone group, higher neutrophil/Lymphocyte ratio (HR = 2.40, CI, 1.351–4.185, P = 0.003), lower PaO2/FiO2, 2 days after treatment, (HR = 1.147, 95% CI, 1.002–1.624, P < 0.0001) independently predicted higher probability of mortality. Dexamethasone showed better survival in severe COVID-19 compared to TCZ. Considering the risk factors mentioned here is crucial when dealing with severe COVID-19 cases.</p> <p>Clinical trial registration No clinicalTrials.gov: Nal protocol approved by Hospital Authorities, for data collection and for participation in CT04519385 (19/08/2020).</p><h2>Other Information</h2> <p> Published in: Scientific Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1038/s41598-021-88086-x" target="_blank">http://dx.doi.org/10.1038/s41598-021-88086-x</a></p>2022-11-22T21:17:17ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1038/s41598-021-88086-xhttps://figshare.com/articles/journal_contribution/Short_term_survival_of_critically_ill_COVID-19_Egyptian_patients_on_assisted_ventilation_treated_by_either_Dexamethasone_or_Tocilizumab/21598230CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215982302022-11-22T21:17:17Z |
| spellingShingle | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab Alaa Rashad (14152917) Medical microbiology Multidisciplinary |
| status_str | publishedVersion |
| title | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab |
| title_full | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab |
| title_fullStr | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab |
| title_full_unstemmed | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab |
| title_short | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab |
| title_sort | Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab |
| topic | Medical microbiology Multidisciplinary |